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The aim of the study was the assessment of the von Willebrand antigen (vWF Ag), E-selectin, and P-selectin concentration in
blood plasma of patients with pseudoexfoliation syndrome (PEX). The group studied comprised 30 patients with PEX, aged from
50 to 86 years (mean 73, SD ± 8 years). Patients with cardiovascular and cerebrovascular diseases, diabetes mellitus, infectious
disease, cancer, renal or liver insuﬃciency, connective tissue disease, current smoking, and hormone, antiplatelet, hypolipidemic,
antioxidant, or antihypertensive drug therapy were excluded from the study. Each subject underwent a complete ophthalmological
examination. Venous blood samples from the cubital vein were taken into sodium citrate solution. VWF Ag, sP-selectin, and
sE-selectin concentration were determined by a commercially available enzyme-linked immunosorbent assay (MedSystems,
Diagnostica Stago/Roche, R&D). Concentrations of vWF Ag, soluble E-selectin, and soluble P-selectin in blood plasma in the
study group were compared with the levels in blood plasma in the control group. No signiﬁcant diﬀerences were found between
the groups. Our results indicate that there might be no correlation between PEX and such endothelial cell markers as vWF Ag, sP-
selectin, andsE-selectin concentrations. Sincethestudysizeislimited, furtherinvestigations toconﬁrm thatthere is noassociation
between endothelial dysfunction in PEX and risk of future cardiovascular disease are necessary.
1.Introduction
Pseudoexfoliation syndrome (PEX) is a common age-related
ﬁbrillinopathy of unknown cause, primarily manifested in
eyes by the accumulation of microscopic granular amyloid-
like protein ﬁbers. Originally, PEX was thought to be limited
to the anterior segment of the eye, recent studies have
indicated, however, that pseudoexfoliative material may be
present in blood vessels; impaired endothelial function can
be observed [1–3]. Since endothelial dysfunction is an inde-
pendent predictor of future cardiovascular events, its pres-
ence in PEX syndrome patients might suggest an increased
vascular risk [4–6]. Connection between inﬂammatory
markers and markers of endothelial dysfunction favours the
hypothesis that also inﬂammation could be involved in the
etiopathogenesis of vascular disease [7]. An established
marker of endothelial damage or dysfunction is von Wille-
brand factor (vWF) which is considered as biomarker in
etiologic pathway of arteriosclerotic vascular disease [8].
The selectin family of cellular adhesion molecules (CAMs)
plays a prominent role in immune/inﬂammatory responses
[9, 10]. The aim of our study is to determine concentrations
of biomarkers which may, according to the literature [11],
precede the symptoms of vascular diseases, in patients with
PEX and no other ocular nor systemic diseases. The present
study is, to the best of our knowledge, the ﬁrst one to
evaluate vWF Ag and sCAMs levels in serum of patients with
pseudoexfoliation syndrome.
2. Patients andMethods
Among 143, consecutive patients with PEX 113 were ex-
cluded based on general or ocular exclusion criteria. This2 The Scientiﬁc World Journal
prospective study involved 30 patients (18 females and 12
males) and 37 control subjects (25 females and 12 males)
without PEX nor any history of systemic disease.
ThestudyhasbeenapprovedbytheMedicalEthicsCom-
mittee of Collegium Medicum Bydgoszcz Nicolaus Coper-
nicus University in Toru´ n. Written informed consent was
obtained from all study participants. A detailed medical his-
tory was collected from all subjects. Patients with cardiovas-
cular diseases (deﬁned as a history of myocardial infarction,
angina pectoris, heart failure, left ventricular dysfunction,
and peripheral arterial disease), diabetes mellitus, hyper-
tension, cerebrovascular disease, infectious disease, cancer,
renal or liver insuﬃciency, connective tissue disease, Parkin-
son’s disease, current smoking, and hormone, antiplatelet,
hypolipidemic, antioxidant or antihypertensive drug therapy
were excluded from the study. Ocular exclusion criteria in-
cluded a history of other than glaucoma neuropathies,
anterior or posterior segment inﬂammation, chorioretinal
degeneration, and retinal vascular diseases.
Each subject underwent a complete ophthalmological
examination including slit lamp biomicroscopy after pupil
dilation. Venous blood samples from the cubital vein were
taken into sodium citrate solution (9:1). All venepunctures
wereperformedusingminimalvenostasis,after15mininthe
recumbent position. In order to obtain low-platelet plasma,
the blood samples were centrifuged at +4◦Cf o r2 0m i n u t e s
with the speed of 3000 rotations per minute. The citrate
plasma obtained in the procedure was divided into portions
(approx. 200µL) placed in Eppendorf tubes. The material
was then frozen in the temperature of −70◦C until the study
was being conducted. Von WF concentration, E-selectin and
P-selectinlevelsweredeterminedbyacommerciallyavailable
enzyme-linked immunosorbent assay using kits produced by
Bender MedSystems, Diagnostica Stago/Roche, R&D.
Statistical Analysis. The Mann Whitney U test was used to
compare patient and control groups for possible diﬀerences
in vWF concentration and E-selectin and P-selectin levels.
3. Results
The group studied comprised of 60% women and 40% men
and similar rate was observed in the control one (68% versus
32%). There was no signiﬁcant diﬀerence between study and
control group in regards of gender.
Mean age in the studied group was 73 years (SD = 8) and
in control one −57 (SD = 10).
The level of vWF Ag was not markedly elevated in pa-
tients with PEX, as compared to the controls (P = 0.5748).
No signiﬁcant diﬀerences were found in sE-selectin (P =
0.9666) and sP-selectin (P = 0.0519) levels between the pa-
tients with PEX syndrome and the control group. Detailed
results are presented in Table 1.
4. Discussion
The etiology and pathophysiology of PEX still remain unex-
plained. Increased prevalence of the disease in certain
Table 1: Endothelial cell markers in blood plasma of patients with
PEX and controls.
Parameter Study group (median,
Quartile1 & Quartile3)
Control group
(median, quartile1,
quartile3)
von Willebrandt
antigen (%)
67,77
Q1 = 53,59
Q3 = 80,89
66,36
Q1 = 59,55
Q3 = 81,82
sE-selectin
(ng/mL)
40,27
Q1 = 27,94
Q3 = 54,64
40,94
Q1 = 33,16
Q3 = 60,12
sP-selectin
(ng/mL)
86,85
Q1 = 71,16
Q3 = 110,72
100,97
Q1 = 70,35
Q3 = 146,19
populations and observed familial aggregation are compat-
ible with PEX being a complex genetic disorder. A strong
association between two nonsynonymous single nucleotide
polymorphisms (SNPs) in the LOXL1 gene and PEX was
detected [12–16]. Lysyl oxidase (LOX) belongs to a family
of extracellular copper-requiring enzymes that facilitate
cross-linking of collagen and elastane through oxidative
deamination of lysine or hydroxylysine side chains and play a
keyroleincollagenandelastanestabilizing.Forover10years,
PEX has been considered a systemic disease. There are also
suggestions that this disease is linked to disorders impairing
blood vessels [2]. Many authors have observed a connection
between pseudoexfoliation syndrome and cardiovascular or
cerebrovascular diseases [4, 11, 17–19]. Yet, there are no
reports concerning the diﬀerence between PEX which is
accompanied with other morbidities and that without such
comorbidities.
Allingham et al. indicated in their study that pseudoexfo-
liationsyndromewasstronglyassociatedwiththepresenceof
glaucoma,butwasassociatedwithneitherAMDnorsystemic
diseases [20].
Biomarkers of endothelial injury such as vWF, E-selectin,
and P-selectin have been implicated in the development and
progression of vascular diseases [7, 11, 21–27]. So far there
are no reports on correlation between LOXL1 activation
and endothelial dysfunction, vascular injury nor vWF/selec-
tins. Elevated levels of vWF, sE-selectin, and sPselectin may
develop as a result of endothelial damage mediated by hyper-
tension. That’s why patients displaying such diseases were
excluded from the study. The lack of statistically signiﬁcant
diﬀerences in vWF Ag, sE-selectin, and sP-selectin levels
between the group of PEX patients and the control group
in our study suggests that there is no correlation between
PEX and endothelial dysfunction. Thus, nonincreased level
of the selectins in patients with PEX may indicate the lack
of connection between this syndrome and vascular diseases.
Other authors’ results also support such a conclusion [28–
30]. However, it is possible that other factors, such as throm-
bogenicity, are enhanced in PEX and this would increase
the risk of cardiovascular event. Although PEX is thought
to be related with cardiovascular diseases, our research casts
doubt on the existence of such a link. Similarly, TarkkanenThe Scientiﬁc World Journal 3
in his review concluded that there is no evidence that
pseudoexfoliation syndrome or pseudoexfoliation glaucoma
are related to increased mortality from cardiovascular dis-
eases [31]. Nevertheless, the underlying pathogenesis of PEX
might be multifactorial. Because hitherto, a clearcut asso-
ciation of PEX with asystemic diseases is yet to be shown,
further large-scale, randomized clinical studies are required.
5. Conclusion
Our results indicate that there might be no correlation
between PEX and vWF Ag, sP-selectin, and sE-selectin
endothelial cell markers concentrations. The study size is
limited therefore further investigations are required to con-
ﬁrm the lack of association between endothelial dysfunction
and PEX.
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